Kwee L. Yong

London, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 205 publications

Plain language summary of publication of how long people with relapsed multiple myeloma lived after treatment in the IKEMA study: Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone.

Plain language summary of publication of how long people with relapsed multiple myeloma lived after treatment in the IKEMA study: Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone.

Journal: Future oncology (London, England)
Published: June 27, 2026

Immune clues to infection risk in myeloma.

Immune clues to infection risk in myeloma.

Journal: Blood
Published: April 30, 2026

Exercise for myeloma patients with bone disease: a scoping review.

Exercise for myeloma patients with bone disease: a scoping review.

Journal: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
Published: December 23, 2025

Incidence of first and subsequent fractures in multiple myeloma patients: a parallel cohort study using UK CPRD dataset.

Incidence of first and subsequent fractures in multiple myeloma patients: a parallel cohort study using UK CPRD dataset.

Journal: Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA
Published: September 09, 2025

Sequencing BCMA- and GPRC5D-targeting immunotherapies in multiple myeloma: Practical guidance from the European Myeloma Network.

Sequencing BCMA- and GPRC5D-targeting immunotherapies in multiple myeloma: Practical guidance from the European Myeloma Network.

Journal: HemaSphere
Published: September 01, 2025

Recognising disease progression in MGUS and smouldering myeloma: Biomarkers, symptom monitoring and imaging.

Recognising disease progression in MGUS and smouldering myeloma: Biomarkers, symptom monitoring and imaging.

Journal: British journal of haematology
Published: August 08, 2025

Latent effector T cells mediate immunotherapy responses in the bone marrow microenvironment.

Latent effector T cells mediate immunotherapy responses in the bone marrow microenvironment.

Journal: Cancer cell
Published: July 23, 2025

Current quality of life questionnaires are not relevant for assessing QOL issues in multiple myeloma patients in the era of modern therapies: results from a survey with myeloma patients and myeloma healthcare professionals.

Current quality of life questionnaires are not relevant for assessing QOL issues in multiple myeloma patients in the era of modern therapies: results from a survey with myeloma patients and myeloma healthcare professionals.

Journal: Frontiers in oncology
Published: June 30, 2025

Tumour-intrinsic features shape T cell differentiation through precursor to symptomatic multiple myeloma.

Tumour-intrinsic features shape T cell differentiation through precursor to symptomatic multiple myeloma.

Journal: Nature communications
Published: June 22, 2025

Enhanced Risk Stratification of Smoldering Multiple Myeloma with Dynamic Biomarkers: A Multinational, Multicenter Study including 2,270 Participants (PANGEA 2.0).

Enhanced Risk Stratification of Smoldering Multiple Myeloma with Dynamic Biomarkers: A Multinational, Multicenter Study including 2,270 Participants (PANGEA 2.0).

Journal: Research square
Published: June 12, 2025

Enhanced dynamic risk stratification of smoldering multiple myeloma.

Enhanced dynamic risk stratification of smoldering multiple myeloma.

Journal: Nature medicine
Published: May 19, 2025

The Role of Radiotherapy for Patients With Multiple Myeloma in the Modern Era: A Real World Single-Centre Experience.

The Role of Radiotherapy for Patients With Multiple Myeloma in the Modern Era: A Real World Single-Centre Experience.

Journal: EJHaem
Published: May 11, 2025
Showing 1-12 of 205

Last Updated: 09/26/2026